NYU Langone Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, NYU Langone Health sits in the top decile of US sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count).
NYU Langone Health: 1,164 sponsored US clinical trials, 197 recruiting.
NYU Langone Health sponsors 1,164 registered US clinical trials on ClinicalTrials.gov, 197 of them currently recruiting, and 741 completed. 123 of these trials are in Phase 3-4 (later-stage) and 231 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
NYU Langone Health ranks in the top decile of sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
741 of 866 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,164 total, page 6 of 24
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
NCT02621151
Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
NCT02752685
Prone Partial Breast Irradiation (PBI): a Prospective Randomized Trial
NCT02276885
Research on Infarction With Open Arteries Using OCT and CMR
NCT02270359
Prospective Study of Thoracolumbar Spinal Fusion Graft
NCT02297256
Rotator Cuff Sparing Total Arthroplasty
NCT01961986
Study of Women With Acute Coronary Syndromes and Nonobstructive Coronary Artery Disease
NCT00798122
South Asians With Type 2 Diabetes at Risk for Depression
NCT07219667
Permanent Supportive Housing Overdose Prevention+ Study
NCT07214519
Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease
NCT05558267
Optimal Dosing of High-Intensity Locomotor Training for Step Attainment and Locomotor Outcomes in Stroke Patients Undergoing Acute Inpatient Rehabilitation
NCT06637839
A Social Network Approach to Improve HIV Prevention and Substance Use Treatment For People Who Use Drugs
NCT07409350
Sexual and Urinary Function Improvement for Cancer Survivors
NCT06637852
Overdose Prevention Centers and Behavioral Health
NCT06236087
Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation
NCT07644923
Sexual Health Communication Skills Training Intervention for Patients With Prostate Cancer
NCT07655557
Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)
NCT06760533
Perspectives About Online Information
NCT07631858
Altius Peripheral Nerve Stimulation in Amputees After TMR/RPNI
NCT07571239
Psilocybin as a Novel Therapy for Residual Anhedonia
NCT07607938
Cardiac Rehab Referral Nudges
NCT07607522
AIManage Using an AI-driven CDS and Chatbot
NCT07546357
Utilization of a 3D Printed Mechanical Balancer During Total Knee Arthroplasty (TKA)
NCT06654661
Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac
NCT07457307
Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations
NCT07598357
Initiative for Chinese Sex Workers to Promote Wellbeing and Improve HIV Prevention by Reducing intersEctional Stigma
NCT07103525
Prospective Multi-center Study Comparing Pulsed Tm:YAG Laser to Pulse Modulated Holmium Laser in the Treatment of Nephrolithiasis With FANS Access Sheaths
NCT07516106
Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis
NCT07602517
Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS
NCT07567014
High Resolution Pharyngeal Manometry (HRPM) Biofeedback
NCT07508059
Extended Oral Tranexamic Acid After Primary Total Knee Arthroplasty
NCT07494032
Vascular Endothelial Inflammation and Health Status In INOCA (VISION-INOCA)
NCT07586241
Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma
NCT07428148
Understanding the Long-term Impact of COVID-19 in Adults
NCT07498504
RADA16 for Aquablation Day Case
NCT06948331
Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma
NCT07335380
Virtual Assistance for Daily Living: Neurophysiological and Functional Effects in Low Vision
NCT07442461
Telerehabilitation for Shoulder Surgery Recovery
NCT07392502
Nudging Provider Adoption of Clinical Decision Support: Implementation of an EHR-Agnostic Pulmonary Embolism Risk Prediction Tool
NCT07249385
Intraoperative Alignment in Adult Spinal Deformity Surgery
NCT07416565
Head-Only Draping in Pediatric Tonsillectomy
NCT07347301
Adaptive Dietary Intervention (ADI) for Asian Americans With Type 2 Diabetes
NCT07278531
Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter
NCT07296328
INcreasing the Uptake of DSMES Program and Addressing Social Needs in Low-Income VulneRablE Immigrants
NCT07296211
Residual IDH1-Mutant Tumor Cell Quantification Study
NCT07219199
The Feasibility of a Nurse-Initiated Weighted Blanket in Orthopedic Surgical Patients Undergoing Total Knee Arthroplasty
NCT07219329
Communication Compass
NCT07220070
Comparison of Merit Prelude Ideal and Terumo Glidesheath Slender Radial Artery Sheaths
NCT07218406
HEAL-SLE: Holistic Energy for Alleviating Lupus Symptoms
NCT07203157
Use of Text Messaging Reminders to Increase FIT Completion Among Patients at the NYU FHCs
NCT06632054
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 99 |
| Phase 2 | 132 |
| Phase 3 | 28 |
| Phase 4 | 95 |
Therapeutic Areas
What is open in the NYU Langone Health pipeline
197 recruiting of 1,164 indexed (17% open); 741 completed (64%).
Phase mix: 123 late (III/IV) vs 231 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NYU Langone Health: open-pipeline peers nationwide
Peers matched on 1,164 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,164 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 17% open enrollment (± trial volume)
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
- University of Utah · 17% recruiting · 818 trials
Related
What to do with this NYU Langone Health page
1,164 registered trials is a research-attention snapshot, not an endorsement of NYU Langone Health or any single study.
- 197 of NYU Langone Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition NYU Langone Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NYU Langone Health pipeline card: 1,164 registered trials from official public datasets.Report a data error.